astrazeneca - dofaq.co
AstraZeneca leaps after smashing first-quarter forecasts
Reuters - 25 Apr 2024
AstraZeneca leaps after smashing first-quarter forecasts ...
AstraZeneca trounces Q1 estimates as resilient demand fuels growth
Business Standard - 25 Apr 2024
AstraZeneca trounces Q1 estimates as resilient demand fuels growth ...
AstraZeneca profit up on strong sales of cancer drugs
ETHealthWorld - 25 Apr 2024
AstraZeneca profit up on strong sales of cancer drugs ...
AstraZeneca CFO on Earnings, US Inflation Reduction Act, China Market
Bloomberg - 25 Apr 2024
AstraZeneca CFO on Earnings, US Inflation Reduction Act, China Market ...
AstraZeneca Stock Flirts With Breakout As Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge
Investor's Business Daily - 25 Apr 2024
AstraZeneca Stock Flirts With Breakout As Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge ...
AstraZeneca reports bumper revenue in Q1 2024 on strong drug demand
Euronews - 25 Apr 2024
AstraZeneca reports bumper revenue in Q1 2024 on strong drug demand ...
AstraZeneca shares jump on much stronger Q1 top and bottom line
Investing.com India - 25 Apr 2024
AstraZeneca shares jump on much stronger Q1 top and bottom line ...
AstraZeneca’s Profit Gains on Sales of Cancer Drugs
Bloomberg - 25 Apr 2024
AstraZeneca’s Profit Gains on Sales of Cancer Drugs ...
AstraZeneca ADR earnings beat by $1.10, revenue topped estimates
Investing.com India - 25 Apr 2024
AstraZeneca ADR earnings beat by $1.10, revenue topped estimates ...
Sanofi and AstraZeneca Scrap Several Early-Stage Programs in Q1
BioSpace - 25 Apr 2024
Sanofi and AstraZeneca Scrap Several Early-Stage Programs in Q1 ...
AstraZeneca CEO says platform deals largely done after M&As in vaccines, radioligand, cell therapy
FiercePharma - 25 Apr 2024
AstraZeneca CEO says platform deals largely done after M&As in vaccines, radioligand, cell therapy ...
AstraZeneca Voydeya approved in EU as add-on treatment to ravulizumab or eculizumab for adults with PNH...
Medical Dialogues - 26 Apr 2024
AstraZeneca Voydeya approved in EU as add-on treatment to ravulizumab or eculizumab for adults with PNH... ...
AstraZeneca posts $2.18bn profit after tax in Q1 2024
Pharmaceutical Technology - 26 Apr 2024
AstraZeneca posts $2.18bn profit after tax in Q1 2024 ...
AstraZeneca Plc (AZN) Q1 2024 Earnings Call Transcript
The Motley Fool - 25 Apr 2024
AstraZeneca Plc (AZN) Q1 2024 Earnings Call Transcript ...
AstraZeneca encounters a surge in shares as profits exceed expectations, buoyed by demand for cancer drugs
Fortune - 25 Apr 2024
AstraZeneca encounters a surge in shares as profits exceed expectations, buoyed by demand for cancer drugs ...
AstraZeneca Gets a Boost From Sales of Its Cancer Drugs
Investopedia - 25 Apr 2024
AstraZeneca Gets a Boost From Sales of Its Cancer Drugs ...
AstraZeneca’s Lynparza to dominate PARP inhibitors market with $4 bn in sales by 2027: GlobalData
Express Pharma - 25 Apr 2024
AstraZeneca’s Lynparza to dominate PARP inhibitors market with $4 bn in sales by 2027: GlobalData ...
Europe falling behind US and China in pharma innovation, warns AstraZeneca chief
Financial Times - 25 Apr 2024
Europe falling behind US and China in pharma innovation, warns AstraZeneca chief ...
AstraZeneca's Lynparza to remain dominant in PARP inhibitors market
BioPharma-Reporter.com - 24 Apr 2024
AstraZeneca's Lynparza to remain dominant in PARP inhibitors market ...